Shah Sanjiv J
Center for Heart Failure, Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine, 676 N. St. Clair Street, Suite 600, Chicago, IL 60611, USA.
Curr Rheumatol Rep. 2009 Apr;11(2):89-96. doi: 10.1007/s11926-009-0013-5.
Pulmonary arterial hypertension (PAH) is a devastating complication of systemic sclerosis (SSc). Although there are screening tests for PAH, such as carbon monoxide diffusing capacity and Doppler echocardiography, these tests are far from perfect, patients are still identified late in the course of disease, and the underlying mechanisms of SSc-associated PAH are poorly understood. Understanding the genetic differences between those patients with SSc who do and do not develop PAH may improve our ability to identify and treat patients earlier in the course of disease. To date, only a few candidate gene association studies and one gene expression analysis have investigated the genetics of PAH in SSc. These studies highlight the important opportunities and challenges for exploration of genetics of complex traits. By appreciating the optimal conduct of genetic studies, along with the role of bioinformatics resources such as the International HapMap database, investigators and clinicians will be better equipped to understand the genetics of SSc-associated PAH.
肺动脉高压(PAH)是系统性硬化症(SSc)的一种严重并发症。尽管有针对PAH的筛查测试,如一氧化碳弥散能力和多普勒超声心动图,但这些测试远非完美,患者在疾病进程中仍被发现较晚,而且SSc相关PAH的潜在机制仍知之甚少。了解患PAH和未患PAH的SSc患者之间的基因差异,可能会提高我们在疾病进程中更早识别和治疗患者的能力。迄今为止,仅有少数候选基因关联研究和一项基因表达分析对SSc中PAH的遗传学进行了研究。这些研究凸显了探索复杂性状遗传学的重要机遇和挑战。通过了解基因研究的最佳实施方式,以及诸如国际人类基因组单体型图(HapMap)数据库等生物信息学资源的作用,研究人员和临床医生将能更好地理解SSc相关PAH的遗传学。